skip to primary navigationskip to content

Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

last modified Oct 05, 2016 03:46 PM
Amadeus Capital Partners, the global technology investor, has made an early-stage investment of £1.5 million in ideaSpace alumni Healx, a Cambridge based healthcare company that seeks new uses for existing drugs in the fight against rare diseases.
Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

Dr Tim Guilliams, Healx CEO

Healx, founded and based in Cambridge, operates in the fast-growing drug ‘repurposing’ sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their unique model engages directly with patient advocacy groups, allowing them to lead the way in personalised healthcare for rare diseases.

Hermann Hauser, Partner and co-Founder of Amadeus Capital Partners, said, “Healx has taken advances in machine learning, data mining and analytics and combined them with deep pharma and life sciences expertise to address a growing need in the healthcare sector. With huge pressure on R&D budgets, drug repositioning will be essential in the fight against rare diseases. With this investment, Healx will take up a leadership position in the drug repurposing sector, expected to be worth over $31 billion by 2020.”

Healx has a scalable technology platform which allows it to match potential treatments to rare conditions and patients. Thanks to its data mining approach, the company aims to complete its drug repurposing studies within six months, much faster than historical literature-based studies.

While there are around 8,000 rare diseases – disorders affecting fewer than 1 in 2,000 people in Europe – only about 500 have a cure. Many are linked to genetics and children account for some 75% of identified cases. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.

Sales of ‘orphan’ drugs designed to treat a specific rare condition have been growing following changes in regulation and tax incentives in the US, with the market forecast to reach $178 billion in 2020. However, as only a small proportion of the population is affected by a particular rare disease, the justification for investing large sums in clinical trials remains a barrier to innovation.

Tim Guilliams, Chief Executive, Healx, commented: “Studies into rare medical conditions have long failed to receive adequate funding. By repurposing existing drugs to combat rare diseases, Healx is able to find potential treatments at a fraction of the cost and in a much shorter timeframe than developing a new drug. With this investment, Healx will have the resources to expand our technology platform and accelerate our drug review process to find treatments to many more devastating illnesses.”

To read more information, click here.

RSS Feed Latest news

Conferences: Get the Most Out of Your Trade Show Experience

Jul 31, 2019

Exhibiting at a conference can be an extremely effective way to meet with potential customers and generate leads, as well as build your start-ups brand presence and create a buzz. But they can be expensive and if not planned well, can waste your small company’s limited resources. Advanced and strategic planning is key to making the most of the experience. So we asked two of our founders, Vaughan Wittorff, Co-Founder & Chief Commercial Officer at PetaGene, and John Pettigrew, Founder and CEO of We Are Futureproofs, for their thoughts on how to approach an exhibition.

Celebrating World Environment Day - Polysolar’s Contribution to Saving our Planet

Jun 05, 2019

ideaSpace exists to support founders with scalable innovative ideas which could potentially address global threats like climate change. To celebrate World Environment Day we spoke to Hamish Watson, founder of ideaSpace alumni company Polysolar – a leader in the provision of solar PV glass for energy generation in buildings. He took us through Polysolar’s story, from product inception to where it is today, and shared his thoughts on the secret to the company’s success, the challenges that have shaped its growth, and some advice on crowdfunding.

View all news